z-logo
open-access-imgOpen Access
Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection
Author(s) -
Mark A. Marzinke,
William Clarke,
Lei Wang,
Vanessa Cummings,
Ting-Yuan Liu,
Estelle PiwowarManning,
Autumn Breaud,
Sam Griffith,
Susan Buchbinder,
Steven Shoptaw,
Carlos del Rı́o,
Manya Magnus,
Sharon Mannheimer,
Sheldon D. Fields,
Kenneth H. Mayer,
Darrell P. Wheeler,
Beryl A. Koblin,
Susan H. Eshleman,
Jessica M. Fogel
Publication year - 2013
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cit672
Subject(s) - medicine , antiretroviral drug , human immunodeficiency virus (hiv) , drug , sida , clinical trial , lentivirus , viral load , antiretroviral therapy , antiretroviral treatment , viral disease , immunology , virology , pharmacology
In The HIV Prevention Trials Network 061 study, 155 human immunodeficiency virus (HIV)-infected men reported no prior HIV diagnosis; 83 of those men had HIV RNA levels of <1000 copies/mL at enrollment. Antiretroviral drug testing revealed that 65 of the 83 (78.3%) men were on antiretroviral treatment. Antiretroviral drug testing can help distinguish between newly diagnosed and previously diagnosed HIV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom